379 related articles for article (PubMed ID: 34806342)
1. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
2. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
3. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F; Balbi GGM; Aikawa NE; Silva CA; Kupa LVK; Medeiros-Ribeiro AC; Yuki EF; Pasoto SG; Saad CG; Borba EF; Seguro LPC; Pedrosa T; Oliveira VAA; Costa ALCS; Ribeiro CT; Santos REB; Andrade DCO; Bonfá E
Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.
Sampaio-Barros PD; Medeiros-Ribeiro AC; Luppino-Assad AP; Miossi R; da Silva HC; Yuki EFVN; Pasoto SG; Saad CGS; Silva CA; Kupa LVK; Deveza GBH; Pedrosa TN; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI169-SI174. PubMed ID: 34894235
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR; Dagostin MA; Caparbo VF; Sales LP; Pasoto SG; Silva CA; Yuki EFN; Saad CGS; Medeiros-Ribeiro AC; Kupa LVK; Fusco SRG; Martins VAO; Martins CCMF; Barbas CV; Shinjo SK; Aikawa NE; Bonfa E
Clinics (Sao Paulo); 2023; 78():100150. PubMed ID: 36529052
[TBL] [Abstract][Full Text] [Related]
7. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
Medeiros-Ribeiro AC; Aikawa NE; Saad CGS; Yuki EFN; Pedrosa T; Fusco SRG; Rojo PT; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Ribeiro CT; Deveza GBH; Martins VAO; Silva CA; Lopes MH; Duarte AJS; Antonangelo L; Sabino EC; Kallas EG; Pasoto SG; Bonfa E
Nat Med; 2021 Oct; 27(10):1744-1751. PubMed ID: 34331051
[TBL] [Abstract][Full Text] [Related]
9. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
[TBL] [Abstract][Full Text] [Related]
10. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
Medeiros-Ribeiro AC; Bonfiglioli KR; Domiciano DS; Shimabuco AY; da Silva HC; Saad CGS; Yuki EFN; Pasoto SG; Araujo CSR; Nakai TL; Silva CA; Pedrosa T; Kupa LVK; Silva MSR; Balbi GGM; Kallas EG; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 May; 81(5):710-719. PubMed ID: 35135832
[TBL] [Abstract][Full Text] [Related]
11. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
[TBL] [Abstract][Full Text] [Related]
12. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
Assawasaksakul T; Sathitratanacheewin S; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Kittanamongkolchai W
RMD Open; 2021 Dec; 7(3):. PubMed ID: 34862313
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients.
Silva CA; Medeiros-Ribeiro AC; Kupa LVK; Yuki EFN; Pasoto SG; Saad CGS; Fusco SRG; Pereira RMR; Shinjo SK; Halpern ASR; Borba EF; Souza FHC; Guedes LKN; Miossi R; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Andrade DCO; Seguro LPC; Fuller R; Sampaio-Barros PD; Assad APL; Moraes JCB; Goldenstein-Schainberg C; Giardini HAM; Silva HC; Martins VAO; Villamarin LEB; Novellino RS; Sales LP; Araújo CSR; Silva MSR; Filho DMN; Lopes MH; Duarte AJS; Kallas EG; Aikawa NE; Bonfa E
Nat Commun; 2022 Oct; 13(1):5801. PubMed ID: 36192386
[TBL] [Abstract][Full Text] [Related]
15. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
Gualano B; Saad CGS; Sieczkowska SM; Lemes ÍR; da Silva RP; Pinto AJ; Mazzolani BC; Smaira FI; Gil S; Oliveira-Junior G; Aikawa NE; Medeiros-Ribeiro AC; Silva CA; Yuki EFN; Pasoto SG; Pereira RMR; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Roschel H; Bonfa E
J Appl Physiol (1985); 2022 Mar; 132(3):682-688. PubMed ID: 35142560
[TBL] [Abstract][Full Text] [Related]
18. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
20. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups.
Ferri C; Ursini F; Gragnani L; Raimondo V; Giuggioli D; Foti R; Caminiti M; Olivo D; Cuomo G; Visentini M; Cacciapaglia F; Pellegrini R; Pigatto E; Urraro T; Naclerio C; Tavoni A; Puccetti L; Varcasia G; Cavazzana I; L'Andolina M; Ruscitti P; Vadacca M; Gigliotti P; La Gualana F; Cozzi F; Spinella A; Visalli E; Dal Bosco Y; Amato G; Masini F; Pagano Mariano G; Brittelli R; Aiello V; Caminiti R; Scorpiniti D; Rechichi G; Ferrari T; Monti M; Elia G; Franceschini F; Meliconi R; Casato M; Iannone F; Giacomelli R; Fallahi P; Santini SA; Zignego AL; Antonelli A
J Autoimmun; 2021 Dec; 125():102744. PubMed ID: 34781162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
